Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Bioventure JCR Develops Transplant Cellular Therapy

This article was originally published in PharmAsia News

Executive Summary

Japan's JCR Pharmaceuticals, with the help of Mochida Pharmaceutical, has in two phases of trials, a treatment aimed at reducing the side effects of bone marrow transplants. JCR, a bioventure, has the cellular therapy JR-031 in Phase I and Phase II trials simultaneously. The treatment involves cultured human mesenchymal stem cells taken from the spinal fluid of healthy people and injected into a transplant patient. The work is being done in cooperation with Mochida and JCR expects to complete both sets of trials in 2011. If successful, JR-031 would be Japan's first cellular therapy. (Click here for more - a subscription may be required
UsernamePublicRestriction

Register

SC072677

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel